Detailed company information
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 03, 2026
Earnings Transcript for 2025 - Q4Released: Feb 26, 2026
Earnings Transcript for 2025 - Q3Released: Nov 03, 2025
Earnings Transcript for 2025 - Q2Released: Aug 04, 2025
Earnings Transcript for 2025 - Q1Released: May 05, 2025
Earnings Transcript for 2024 - Q4Released: Mar 03, 2025
Earnings Transcript for 2024 - Q3Released: Nov 05, 2024
Earnings Transcript for 2024 - Q2Released: Aug 02, 2024
Earnings Transcript for 2024 - Q1Released: May 08, 2024
Earnings Transcript for 2023 - Q4Released: Feb 27, 2024
Earnings Transcript for 2023 - Q3Released: Nov 02, 2023
Earnings Transcript for 2023 - Q2Released: Aug 05, 2023
Earnings Transcript for 2023 - Q1Released: May 08, 2023
Earnings Transcript for 2022 - Q4Released: Mar 03, 2023
Earnings Transcript for 2022 - Q3Released: Nov 06, 2022
Earnings Transcript for 2022 - Q2Released: Aug 08, 2022
Earnings Transcript for 2022 - Q1Released: May 09, 2022
Earnings Transcript for 2021 - Q4Released: Mar 01, 2022
Earnings Transcript for 2021 - Q3Released: Nov 15, 2021
Earnings Transcript for 2021 - Q2Released: Aug 09, 2021
Earnings Transcript for 2021 - Q1Released: May 11, 2021
Earnings Transcript for 2020 - Q4Released: Mar 08, 2021
Earnings Transcript for 2020 - Q3Released: Nov 02, 2020
Earnings Transcript for 2020 - Q2Released: Aug 09, 2020
CGEM Cullinan Therapeutics, Inc.
Syndax forecasts that 70-80% of KMT2A patients will receive revumenib as post-transplant maintenance within 1-2 years, reflecting rapid adoption and enhanced physician confidence post-Q4 2025.
Read post
Dafinchi
